Digest Network Come funziona
Network
/
Società
Ne
Non verificato

NextPoint Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieOncologia

4 comunicati stampa

Guarda tutti i comunicati
25/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
Fonte
NextPoint Therapeutics
Emittente
Business Wire
1.00
0
07/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
NextPoint Therapeutics to Highlight Antibody-Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings Targeting Novel B7-H7 Pathway at AACR Annual Meeting
Fonte
NextPoint Therapeutics
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024
Fonte
NextPoint Therapeutics
Emittente
Business Wire
1.00
0
05/09/2024
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors
Fonte
NextPoint Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0